Acute hepatitis B notification rates in Flanders, Belgium, 2009 to 2017.
Adolescent
Adult
Belgium
/ epidemiology
Child
Child, Preschool
Disease Notification
/ statistics & numerical data
Female
Hepatitis B
/ epidemiology
Hepatitis B Vaccines
/ administration & dosage
Homosexuality, Male
Humans
Immunization Programs
Infant
Infant, Newborn
Male
Mandatory Reporting
Population Surveillance
/ methods
Program Evaluation
/ methods
Risk Factors
Sexual Behavior
Vaccination
Vaccination Coverage
Belgium
acute hepatitis B
antenatal screening
blood-borne infections
epidemiology
hepatitis B vaccines
hepatitis B virus
men who have sex with men - MSM
prevention and control
public health policy
sexually transmitted infections
vaccines and immunisation
Journal
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
entrez:
1
8
2019
pubmed:
1
8
2019
medline:
25
7
2020
Statut:
ppublish
Résumé
BackgroundBelgium is a low-endemic country for hepatitis B. Universal hepatitis B vaccination in infants with catch-up in the age cohort of 10-13 year-olds began in 1999.AimsOur objective was to evaluate the effect of prevention and control strategies on acute hepatitis B notification rates in Flanders (Belgium) from 2009 to 2017.MethodsThis observational study collected demographic data and risk factors for acute hepatitis B from mandatory notifications to the Agency for Care and Health.ResultsIn Flanders, acute hepatitis B notification rates per 100,000 population decreased from 1.6 in 2009 to 0.7 in 2017. These rates declined in all age groups: 0-4-year-olds: 0.6 to 0.0, 5-14-year-olds: 0.2 to 0.0, 15-24-year-olds: 0.8 to 0.7, 25-34-year-olds: 3.4 to 1.1 and ≥ 35-year-olds: 1.59 to 0.7. There was also a downward trend in acute hepatitis B notification rates in native Belgians and first-generation migrants. Among 15-24-year-olds and 25-34-year-olds, a possible reversal of the decreasing trend was observed in 2016 and 2015, respectively. Among 548 acute hepatitis B cases, the main route of transmission was sexual activity (30.7%), and the pattern of transmission routes over time showed an increasing proportion of sexual transmission in men who have sex with men (MSM) after 2014. During the period from 2009 to 2017, five mother-to-child transmissions were reported.ConclusionsPrevention and control strategies were effective in reducing the acute hepatitis B notification rate. However, stronger prevention and control measures are needed in adult risk groups, particularly MSM.
Identifiants
pubmed: 31362809
doi: 10.2807/1560-7917.ES.2019.24.30.1900064
pmc: PMC6668289
doi:
Substances chimiques
Hepatitis B Vaccines
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Références
Sex Transm Infect. 2003 Apr;79(2):157-9
pubmed: 12690142
Int J STD AIDS. 2004 Jul;15(7):493-4
pubmed: 15228740
Infection. 2004 Oct;32(5):278-81
pubmed: 15624891
Int J STD AIDS. 2005 Nov;16(11):744-8
pubmed: 16303070
Eur J Epidemiol. 2007;22(3):195-202
pubmed: 17356926
Vaccine. 2007 Jun 21;25(26):4940-8
pubmed: 17524528
Pediatrics. 2008 Mar;121(3):e428-34
pubmed: 18310163
Travel Med Infect Dis. 2008 Sep;6(5):315-20
pubmed: 18760256
J Med Virol. 2010 Apr;82(4):546-55
pubmed: 20166185
Epidemiol Infect. 2014 Feb;142(2):251-61
pubmed: 23689103
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):707-15
pubmed: 23703489
Lancet. 2014 Dec 6;384(9959):2053-63
pubmed: 24954675
Gac Sanit. 2014 Nov-Dec;28(6):492-5
pubmed: 25042394
Lancet. 2015 Oct 17;386(10003):1546-55
pubmed: 26231459
Lancet. 2016 Sep 10;388(10049):1081-1088
pubmed: 27394647
Microb Cell. 2016 Sep 05;3(9):420-437
pubmed: 28357379
Lancet Glob Health. 2017 Dec;5(12):e1208-e1220
pubmed: 29074410
Euro Surveill. 2018 Feb;23(6):
pubmed: 29439751
Gastroenterology. 2019 Jan;156(2):297-310
pubmed: 30391470
J Med Virol. 2019 Aug;91(8):1479-1488
pubmed: 30870580
J Infect Dis. 1985 Apr;151(4):599-603
pubmed: 3973412
Lancet. 1983 Nov 12;2(8359):1099-102
pubmed: 6138642
N Engl J Med. 1997 Jun 26;336(26):1855-9
pubmed: 9197213
Eur J Epidemiol. 1997 Apr;13(3):275-80
pubmed: 9258525